Adamis Pharmaceuticals Corporation

Greetings, and welcome to Adamus Pharmaceuticals' first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. If anyone should require operator assistance during a conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Robert Oh, with ICR Westwick. Thank you, sir. You may proceed.

Thank you, operator. Welcome to the Atomos Pharmaceuticals first quarter 2023 financial results and corporate update conference call. Joining me on the call today are members of the Atomos executive team, including Chief Executive Officer, David J. Margulio, and Chief Financial Officer, David Benedicto. And once again, DMK Pharmaceuticals CEO, Dr. Eboo Versi, will also join the call. Our format for this call will consist of prepared remarks from Atomos Management and Dr. Versi, followed by a Q&A session. This call is being webcast and will be available for replay in the investor section of our website at atomospharmaceuticals.com. In today's call, we will make certain forward-looking statements regarding our business based on current information and expectations. Those statements speak only as of today and accept As required by law, we do not assume any duty to update in the future any forward-looking statement made today. Of course, any forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements that we make today. Additional information concerning factors that could affect our business and financial results is included in our most recent annual report on Form 10-K, filed with the Securities and Exchange Commission, and in other subsequent filings that we make with the SEC. These are available on the SEC's website at sec.gov or on Atomos' website. Now, let me hand the call over to David Margulio, CEO of Atomos.

Thank you, Robert, and thanks to everyone for joining our call this afternoon. Today has certainly been an exciting day for all of us here at Atomos. As you may know, earlier we hosted a special meeting of stockholders during which stockholders approved both measures that will enable us to proceed with the merger with DMK Pharmaceuticals. Following the stockholder meeting, the Atomos Board of Directors met to review the voting results. After the board meeting, we filed our 10Q with financial results for the first quarter ending March 31st, from which David Benedicto will provide a summary of in a few moments. During the board meeting, among other matters, the board discussed the necessity for meeting the minimum bid price requirement to avoid being delisted from NASDAQ. The board determined that it is in the best interest of the company and its stockholders to avoid delisting and therefore authorized the company to effect a reverse split in the near future to be able to reach the closing price of over $1 a share for at least 10 consecutive trading days prior to the NASDAQ imposed deadline of June 26. We notified NASDAQ of our plan and in the coming days we intend to further describe the timing and the ratio for the reverse stock split. Following the reverse split and upon the satisfaction or waiver of the remaining closing conditions, we intend to close the merger with DMK. This merger has been the result of countless hours of work over the last six months by the employees of both companies, as well as our respective auditors, lawyers, and other advisors. I believe I speak for everyone involved when I say that this merger is truly an exciting milestone in the history of both companies, and we have great expectations for the future of the combined company. Before turning it over to our incoming CEO, Dr. Eboo Versi, to provide a glimpse of that future. I will ask David Benedicto to summarize the first quarter 2023 financials. David.